Healthcare - Press Releases

Conference Call and Webcast Scheduled for Thursday, February 6

ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast.

BURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024.

WASHINGTON, Jan. 30, 2025 /PRNewswire/ --Paralyzed Veterans of AmericaChief Executive Officer Carl Blake releases statement following remarks made by President Donald Trump at a press conference addressing yesterday's tragic crash of American Airlines Flight 5342 and an Army Blackhawk helicopter.

SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies by Fortune magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.

TORONTO and DALLAS, Jan. 30, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced that Bristol Investor Relations will host an investor webcast Thursday, February 6, 2025 at 2:00 PM ET.

AUSTIN, Texas, Jan. 30, 2025 /PRNewswire/ -- Dr. RogerHollis from the University of California, Los Angeles, project scientist from the laboratory of Dr. Donald Kohn, a world leader in developing gene replacement therapies using blood stem cells, has been awarded a $5.8 million translational research award from the California Institute for Regenerative Medicine (CIRM) to further support the development of a hematopoietic stem cell gene therapy (HSC-GT) to treat Angelman syndrome (AS).

LOS ANGELES, Jan. 30, 2025 /PRNewswire/ --The DJS Law Groupannounces that it is investigating claims on behalf of investors ofCARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ: CRGX) for violations of the securities laws.

MOBILE, Ala., Jan. 30, 2025 /PRNewswire/ -- AltaPointe Health, a leading provider of behavioral health services in the Mobile community, has reached a significant milestone in its mission to support mental health and crisis intervention. Since opening its Behavioral Health Crisis Center in May 2021, the facility has saved the community more than$50 millionin associated costs.

Restore Hyper Wellness Expands Skin Health Offerings with 4 Facials, 4 Chemical Peels, and Retail Home Care Solutions from Jan Marini Skin Research

BLINCYTO, ,

The MASH treatment landscape is evolving rapidly, driven by a diverse array of therapeutic classes, each with unique mechanisms and potential impacts. The forecast period reveals significant shifts and emerging trends that will shape future market dynamics.

CHICAGO, Jan. 30, 2025 /PRNewswire/ -- The National Association for Healthcare Quality(NAHQ) has announced its 2025 board members and has acknowledged those in leadership positions.Patricia Resnik, MJ, MBA, RRT, FACHE, CPHQ, CHC, CHPC, remains in the role of its 2025 president; Nidia Williams, PhD, MBB, CPHQ, FNAHQ, serves as immediate past president; April M. Taylor, MS, MHA, FACHE, CMQ/OE, CLSSBB, CPHQ, CPPS, is president-elect; andCathy Duquette, PhD, MBA, RN, NEA-BC, CPHQ, FNAHQ, is secretary/treasurer.

BLINCYTOwurde zustzlich zu einer mehrphasigen konsolidierenden Chemotherapie eingesetzt und senkte das Sterberisiko im Vergleich zu einer Chemotherapie allein erheblich

First Drug Approved in New Class of Non-Opioid Pain Medicines; Agency Continues to Take Steps to Support New Approaches for Pain Management

JERSEY CITY, N.J., Jan. 30, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA. AVTOZMA is indicated for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19).[1]

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The global genomics marketsize is estimated to grow by USD 5.21 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over3.16% during the forecast period. Rising investments in genomics research and developmentis driving market growth,with a trend towardsadvances in sequencing technologies. However,varying regulations in genomics research and testing poses a challenge. Key market players include 10X Genomics Inc., Abcam plc, Agilent Technologies Inc., Becton Dickinson and Co., BGI Group, Bio Rad Laboratories Inc., Danaher Corp., Eppendorf SE, F. Hoffmann La Roche Ltd., Hamilton Bonaduz AG, Illumina Inc., Myriad Genetics Inc., New England Biolabs Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Promega Corp., QIAGEN NV, Standard BioTools Inc., Thermo Fisher Scientific Inc., and PerkinElmer Inc.

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Report on how AI is redefining market landscape - The global vaccine research marketsize is estimated to grow by USD 21.4 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.84% during the forecast period. High prevalence of infectious diseasesis driving market growth,with a trend towardsadoption of ai to speed up r and d of vaccines. However,high cost of vaccine research, development, and manufacturing poses a challenge. Key market players include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., CanSino Biologics Inc., Creative Biogene, CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Moderna Inc., Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., and Takeda Pharmaceutical Co. Ltd..

11 nouveaux clientsLifeSphere nets, 57 mises en service clients et l'adoption accrue de NavaX

TOKYO, Jan. 29, 2025 /PRNewswire/ --The Global Health Innovative Technology (GHIT) Fundannounced today a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2

Elf neueLifeSphere-Kunden, 57 Kunden, die das System in Betrieb genommen haben, und eine grere Akzeptanz von NavaX

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The globalvaccines marketsize is estimated to grow by USD 193.7 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of almost23% during the forecast period. Increased funding for vaccine development and new vaccine launchesis driving market growth,with a trend towardsdevelopment of nanoparticle vaccines.However,high cost of vaccine research, development, and manufacturing poses a challenge. Key market players include Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co., Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GSK Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson Inc., Merck KGaA, Mitsubishi Chemical Group Corp., Novavax Inc., Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE.

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global gender reassignment surgery marketsize is estimated to grow by USD 374.2 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of over11.2% during the forecast period. Increase in number of people opting for sex change surgeries globallyis driving market growth,with a trend towardsadvancements in medical technology. However,high cost of surgeries poses a challenge. Key market players include Andrew Ives., Boston Childrens Hospital, Boston Medical Center, Chettawut Plastic Surgery Center, CNY Cosmetic and Reconstructive Surgery, Crane Center, Icahn School of Medicine at Mount Sinai, IVAN MANERO CLINIC S.L., Moein Surgical Arts, Oregon Health and Science University, Phuket International Aesthetic Centre PIAC, Plastic Surgery Group of Rochester, Regents of the University of Michigan, Rumer Cosmetic Surgery, Sava Perovic Foundation Surgery, The Johns Hopkins Health System Corp., Transgender Surgery Institute, and University of Pennsylvania Health System.

TOKYO, Jan. 30, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the treatment of IgA nephropathy in Japan.

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The globalambulatory surgical centers marketsize is estimated to grow by USD 25.4 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.03% during the forecast period. Growing cataract ambulatory surgeriesis driving market growth,with a trend towardsincreasing number of partnerships and collaborations. However,financial constraints poses a challenge. Key market players include Advanced Data Systems Corp., Community Health Systems Inc., eClinicalWorks LLC, Envision Healthcare, GE Healthcare Technologies Inc., Healthway Medical Corp. Ltd., McKesson Corp., NextGen Healthcare Inc., NorthShore University HealthSystem, Oracle Corp., Pediatrix Medical Group Inc., Pinnacle Surgery Center LLC, Prospect Medical Holdings Inc., SurgCenter, Surgery Partners Inc., Surgical Information Systems LLC, TeamHealth, Tenet Healthcare Corp., United Health Group Inc., and Veradigm LLC.